Press Release

NEW ORLEANS, LA and LONDON UK, July 30, 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today receipt of Clinical Trial Authorization (CTA) by the Medicines and Healthcare Products Regulatory Agency (MHRA) […]

Revolo Bio Initiating Four Phase 2 Clinical Trials NEW ORLEANS, LA and LONDON UK, July 15, 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that Jonathan Rigby, President and Group CEO,

NEW ORLEANS, LA and LONDON UK, July 1, 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced the appointments of Marla S. Persky and Glen Giovannetti to its Board of Directors. “We

NEW ORLEANS and LONDON – June 23, 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today the approval of an investigational new drug (IND) application by the U.S. Food and Drug Administration

NEW ORLEANS and LONDON, and WALTHAM, Mass and VILNIUS, Lithuania – June 9 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a partnership with Northway Biotech, a

NEW ORLEANS, LA and LONDON UK, May 14, 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that Dr. Roly Foulkes, Chief Scientific Officer, will present information relating to the Company’s lead

– ‘1104 was safe and well-tolerated without serious adverse events  – NEW ORLEANS, LA and LONDON UK, May 4, 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission in patients with autoimmune (‘1805 a protein drug) and allergic disease (‘1104 a

– Agreement ensures supply to support clinical and commercial operations – NEW ORLEANS, LA and LONDON UK, April 15, 2021 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered

— Plans to initiate four Phase 2 trials in second half of 2021 — Exploring additional autoimmune and allergic disease indications for portfolio candidates NEW ORLEANS, LA and LONDON UK, March 5, 2021 – Immune Regulation, today announced it is rebranding as Revolo Biotherapeutics (“Revolo Bio”). The new brand, which will be implemented immediately, comes

Immune Regulation Ltd, announced today that the company will give a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:30 a.m. EST. Group CEO Jonathan Rigby will present information relating to the Company’s immune resetting therapeutics, ‘1104 and ‘1805, that are in clinical development to treat allergic and autoimmune diseases.